Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TTP-8307 is a potent replication of several rhino- and enteroviruses inhibitor.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 954.00 | |
50 mg | 6-8 weeks | $ 1,240.00 | |
100 mg | 6-8 weeks | $ 1,990.00 |
Description | TTP-8307 is a potent replication of several rhino- and enteroviruses inhibitor. |
In vitro | TTP-8307 inhibits the replication of coxsackievirus B3 (CVB3 Nancy) (EC50 : 1.2 μM) and the three poliovirus Sabin strains, as well as coxsackieviruses A16 and A21 (EC50 of 0.85 and 5.34 μM). TTP-8307 inhibits human rhinoviruses (HRVs) 2, 29, 39, 45, 63, and 85. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307[1]. TTP-8307 inhibits OSBP-dependent viruses encephalomyocarditis virus (EMCV) and HCV[2]. |
Molecular Weight | 436.48 |
Formula | C27H21FN4O |
CAS No. | 950225-08-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TTP-8307 950225-08-8 Others TTP 8307 TTP8307 inhibitor inhibit